Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Summary

The primary objective is to determine whether the addition of bevacizumab to a regimen of carboplatin plus paclitaxel significantly improves Progression Free Survival (PFS) for patient with Stage III suboptimally cytoreduced or Stage IV ovarian, primary peritoneal or fallopian tube carcinomas.

Timeline

Start

2006-10

Primary completion

2009-08

Completion

2009-10

Outcome

Outcome not reported

Stopped (Enrollment): “Did not meet accrual goals.”

Drugs

Indications